Press Releases
Latest Novartis Pharmaceuticals Press Releases
Novartis press releases are listed below by date. To read a release, click on its title, or, to access older releases, just scroll down the list.
To view Novartis worldwide press releases,
visit the Novartis AG newsroom.
6-Jan-2009
FDA approves once-yearly Reclast® for osteoporosis in men
12-Dec-2008
First Phase III results for FTY720, a novel oral therapy for MS, show superior efficacy compared to interferon beta-1a
13-Nov-2008
US FDA approves 30-minute onset of action for Focalin® XR, bringing potential benefits to ADHD patients during early morning period
11-Nov-2008
Tekturna®, first approved direct renin inhibitor, effectively lowers high blood pressure in elderly patients
11-Nov-2008
Study shows potential benefits of Xolair® in treating children suffering from moderate or severe persistent allergic asthma inadequately controlled with inhaled corticosteroids
4-Aug-2008
Single-pill combinations Diovan HCT and Exforge approved in US as first-line treatments for high blood pressure
29-Jul-2008
Novartis Makes Accessing Prescription Assistance and Disease Management Programs Simpler and Easier for Patients
28-Jul-2008
Exforge® helps nearly twice as many patients control their high blood pressure compared to amlodipine alone
1-Jul-2008
Novartis Pharmaceuticals Corporation to Appeal Judgment in Alabama Pricing Case
5-Jun-2008
FDA broadens US indication for once-yearly Reclast® as only osteoporosis treatment approved for prevention of fractures after a hip fracture
5-Jun-2008
New data show Tekturna® reduced albuminuria, a key marker of kidney disease, independent of its proven ability to lower blood pressure1
15-Apr-2008
FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment
15-Apr-2008
Patients with early Parkinson's disease show better symptom control and improvements in daily activities with Stalevo than carbidopa/levodopa
11-Apr-2008
Study shows once-yearly Reclast better than risedronate at increasing bone mass in patients with osteoporosis caused by glucocorticoids
31-Mar-2008
Novartis and FDA complete Two-year Cooperative Research and Development Agreement (CRADA) To Define and Test a Process for Qualifying Preclinical Safety Biomarkers
31-Mar-2008
Lotrel, a single-pill combination for treating high blood pressure, reduced cardiovascular events by 20% in high-risk patients
27-Mar-2008
Head-to-head study suggests Focalin® XR provides superior symptom management in the early part of the ADHD patient's day compared to Concerta®
21-Jan-2008
Tekturna HCT®, a single-tablet combination of Tekturna® and a diuretic, receives US approval for treatment of high blood pressure
The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on Novartis' website for historical purposes only. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.
